IGM Biosciences Inc (IGMS) - Total Liabilities
Based on the latest financial reports, IGM Biosciences Inc (IGMS) has total liabilities worth $6.06 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore IGMS long-term investments to assets to see how much of total assets are deployed in long-term investments.
IGM Biosciences Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how IGM Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see IGM Biosciences Inc asset portfolio.
IGM Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of IGM Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kwang Ming Silk Mill Co Ltd
TWO:4420
|
Taiwan | NT$293.81 Million |
|
Alakasa Industrindo Tbk
JK:ALKA
|
Indonesia | Rp12.86 Billion |
|
Optipharm.CO.LTD
KQ:153710
|
Korea | ₩15.42 Billion |
|
NVH Korea Inc
KQ:067570
|
Korea | ₩1.15 Trillion |
|
Botnia Gold AB (publ)
ST:BOTX
|
Sweden | Skr93.42 Million |
|
51 CREDIT CARD DL-00001
F:2JY
|
Germany | €215.87 Million |
|
Shuang-Bang Industrial
TWO:6506
|
Taiwan | NT$1.23 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down IGM Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See IGMS net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how IGM Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for IGM Biosciences Inc (2017–2024)
The table below shows the annual total liabilities of IGM Biosciences Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $217.54 Million | -1.20% |
| 2023-12-31 | $220.18 Million | -2.68% |
| 2022-12-31 | $226.24 Million | +325.10% |
| 2021-12-31 | $53.22 Million | +98.45% |
| 2020-12-31 | $26.82 Million | +26.98% |
| 2019-12-31 | $21.12 Million | -69.75% |
| 2018-12-31 | $69.81 Million | +66.63% |
| 2017-12-31 | $41.89 Million | -- |
About IGM Biosciences Inc
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. As of August 14, 2025, IGM Biosciences, In… Read more